What is the step‑by‑step technique for a smooth extubation when using sevoflurane with target‑controlled infusion remifentanil and rocuronium reversed with sugammadex, and why does sugammadex‑reversed rocuronium sometimes cause more bucking than atracurium reversed with neostigmine?

Smooth Extubation Protocol with Sevoflurane-Remifentanil TCI and Rocuronium-Sugammadex

The increased bucking you're experiencing with sugammadex-reversed rocuronium compared to neostigmine-reversed atracurium is likely due to the rapid, complete reversal of neuromuscular blockade by sugammadex, which unmasks inadequate depth of anesthesia or insufficient remifentanil effect-site concentration during emergence.

Why Sugammadex May Cause More Bucking

The paradox you're observing has a clear mechanistic explanation:

Neostigmine provides a "buffer period" - It takes 10-20 minutes to achieve TOF ratio ≥0.9 1, giving you time to titrate anesthetic depth and allowing remifentanil levels to equilibrate during emergence. This gradual reversal inadvertently masks inadequate anesthetic depth.

Sugammadex reverses too efficiently - It achieves TOF ratio ≥0.9 in 3-5 minutes 1, meaning patients recover full neuromuscular function while still having adequate anesthetic depth for the surgical procedure but insufficient suppression of airway reflexes. Research confirms sugammadex reverses rocuronium-induced blockade 4.7 times faster than neostigmine reverses cisatracurium 2, and this rapid reversal can expose inadequate anesthetic management during emergence.

Critical mechanistic difference: Neostigmine has anticholinergic effects that may suppress airway reflexes through muscarinic mechanisms, while sugammadex is purely a selective encapsulation agent with no direct airway effects 3. Animal studies demonstrate that neostigmine actually impairs upper airway dilator muscle activity when given after complete recovery, whereas sugammadex has no such effect 3.

Step-by-Step Smooth Extubation Protocol

1. Pre-Extubation Preparation (5-10 minutes before end of surgery)

• Verify adequate neuromuscular monitoring: Ensure TOF monitoring is functioning with proper supramaximal stimulation 1
• Target remifentanil Ce: Maintain remifentanil TCI at 1.7 ng/mL effect-site concentration - this is the EC95 for preventing extubation coughing in neurointervention patients 4
• Sevoflurane management: Begin gradual reduction to 0.3-0.5 MAC approximately 10 minutes before anticipated extubation
• Optimize positioning: Semi-sitting position (30-45 degrees) for most patients; lateral decubitus if aspiration risk 5

2. Timing of Sugammadex Administration

Critical principle: Dose sugammadex based on actual TOF count, not arbitrary timing 1:

• TOF count = 4 (shallow block): 1.0 mg/kg sugammadex (reversal in <5 min)
• TOF count = 2 (moderate block): 2.0 mg/kg sugammadex (reversal in <5 min)
• PTC 1-2 (deep block): 4.0 mg/kg sugammadex (reversal in 3-5 min)
• Dose based on ideal body weight for obese patients 1

3. The Critical Window: Managing Remifentanil During Reversal

This is where most bucking occurs - you must bridge the gap between neuromuscular reversal and anesthetic emergence:

• Maintain remifentanil TCI at 1.7 ng/mL until 2-3 minutes before planned extubation 4
• Do NOT stop remifentanil when you give sugammadex - this is the most common error
• Monitor TOF continuously: Wait for TOF ratio ≥0.9 (typically 3-5 minutes with sugammadex) 1
• Only after TOF ≥0.9 is confirmed, begin reducing remifentanil to 1.0-1.2 ng/mL

4. Extubation Sequence

• Sevoflurane: Turn off completely once TOF ≥0.9 achieved
• Remifentanil: Reduce to 1.0 ng/mL approximately 2 minutes before extubation
• Oxygenation: FiO2 = 1.0 5
• Suctioning: Suction oropharynx only (avoid endotracheal suctioning to prevent lung derecruitment) 5
• Deflate cuff using syringe 5
• Extubate during positive pressure at end-inspiration to prevent atelectasis 5
• Stop remifentanil TCI at the moment of extubation

5. Post-Extubation Management

• Continue quantitative TOF monitoring for 15 minutes to detect potential recurarization 1
• Have rescue analgesia ready: Patients will require analgesics sooner with remifentanil (median 35 minutes) compared to longer-acting opioids 6

Common Pitfalls and How to Avoid Them

Pitfall #1: Stopping remifentanil too early

• Sugammadex works so fast that if you stop remifentanil when you give sugammadex, the patient will have full neuromuscular function but inadequate anesthetic depth
• Solution: Maintain therapeutic remifentanil levels (1.7 ng/mL) until TOF recovery is confirmed

Pitfall #2: Inadequate sugammadex dosing

• Underdosing causes delayed reversal or recurarization 1
• Solution: Always dose based on actual TOF/PTC count, not guesswork

Pitfall #3: Extubating before TOF ≥0.9

• Studies show 32-47% of patients are extubated with TOF <0.9 despite monitoring 7
• Solution: Wait for objective confirmation of TOF ≥0.9 before extubation

Pitfall #4: Comparing apples to oranges

• Atracurium with neostigmine gives you a 10-20 minute "grace period" for emergence
• Rocuronium with sugammadex gives you 3-5 minutes
• Solution: Adjust your anesthetic management timeline accordingly - start emergence planning earlier with sugammadex

Why Neostigmine-Atracurium Seems "Smoother"

The perceived smoothness with neostigmine is actually a timing artifact, not superior pharmacology:

• Neostigmine's slow reversal (10-20 minutes) 1 allows gradual lightening of anesthesia
• The anticholinergic co-administration (atropine/glycopyrrolate) may provide additional airway reflex suppression
• You have more time to "feel your way" through emergence
• However, this comes at the cost of potential residual paralysis if you extubate too early

Sugammadex is objectively superior 8, 9, 10 but requires more precise anesthetic management because it eliminates the neuromuscular blockade "buffer" that masks inadequate anesthetic depth.

Evidence-Based Advantages of Your Current Technique

Despite the bucking issue, your rocuronium-sugammadex approach is superior:

• Faster, more complete reversal: 4.7x faster than neostigmine 2
• No anticholinergic side effects: 95% dry mouth with neostigmine vs 5% with sugammadex 9
• No upper airway impairment: Neostigmine decreases upper airway dilator muscle activity by 36%, sugammadex does not 3
• Reliable reversal of deep blocks: Neostigmine cannot reverse deep blocks; sugammadex can 1

The solution is not to abandon sugammadex, but to optimize your remifentanil management during the rapid reversal phase.